Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report

April 2024 in “ Curēus ”

Hanadi Alsatti, Basel AlMalki, Yara Alghamdi

abemaciclib CDK4/6 inhibitor hair loss rash pruritus nail changes vitiligo photosensitivity cutaneous adverse effects

TLDR Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

Abemaciclib, a CDK4/6 inhibitor used for hormone-sensitive HER2-positive metastatic breast cancer, can cause dermatological side effects, including rash, pruritus, hair loss, nail changes, vitiligo, and photosensitivity, though these are less common. These cutaneous adverse effects contribute to 25% of medication discontinuations. This case report details a patient who developed hair, nail, and pigmentary disorders 10 months after starting abemaciclib treatment.

View this study on assets.cureus.com →

Discuss this study in the Community →

Similar Research

5 / 12 results

Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study

research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study

1 citations, July 2023 in “Cancers”

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

research Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment

7 citations, October 2019 in “Annals of palliative medicine”

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

research Managing Hyperglycemia and Rash Associated With Alpelisib: Expert Consensus Recommendations Using the Delphi Technique

1 citations, January 2024 in “NPJ breast cancer”

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis

research Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis

28 citations, July 2017 in “Expert Review of Anticancer Therapy”

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

research Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

4 citations, October 2018 in “Asia-Pacific Journal of Clinical Oncology”

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.